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ABSTRACT 27	
 28	
Extracellular Vesicles (EVs) are released by a wide number of cells including blood cells, 29	
immune system cells, tumor cells, and adult and embryonic stem cells. EVs are an 30	
heterogeneous group of vesicles (~30-1000 nm) known by several different names 31	
including: microparticles, microvesicles, ectosomes, shedding vesicles or exosomes. 32	
The various roles of EVs during parasite-host cell interaction have been described 33	
recently in several diseases, bringing to the fore a novel concept in cell communication 34	
between parasites and host cells. The physiological release of EVs represents a normal 35	
state of the cell raising a metabolic equilibrium between catabolic and anabolic 36	
processes.  Moreover, when the cells are submitted to stress with different inducers or 37	
in pathological situations (malignances, chronic diseases, infectious diseases.), they 38	
respond with an intense and dynamic release of EVs. The EVs released from stimulated 39	
cells versus those that are released constitutively may themselves differ, both physically 40	
and in their cargo. EVs contain protein, lipids, nucleic acids and biomolecules that can 41	
alter cell phenotypes or modulate neighboring cells. In this review, we have summarized 42	
most of the findings involving EVs in certain specific protozoan diseases. We have 43	
commented on strategies  to study the communicative roles of EVs  during parasite host 44	
cell interaction and hypothesized on the  use of EVs for diagnostic, preventative and 45	
therapeutic purposes in infectious diseases. This kind of communication could modulate 46	
the innate immune system and reformulate concepts in parasitism. Moreover, the 47	
information provided within EVs could  provide alternatives in translational medicine.  48	
 49	
  50	
KEY FINDINGS 51	
Extracellular vesicles (exosomes and microvesicles) have different biogenesis 52	
and can be released constitutively or under stimulation during host pathogen 53	
interactions.	54	
Extracellular vesicles contain protein, lipids, nucleic acids and biomolecules 55	
that participate in cellular communication with other cells.	56	
Extracellular vesicles have a potential diagnostic value.	57	
 58	
INTRODUCTION 59	
Neglected diseases, including leishmaniasis and Chagas disease, cause many 60	
thousands of deaths per annum, and are prevalent in several regions of the world, but 61	
mainly in underdeveloped regions, associated with poverty,   in Asia, Africa and the 62	
Americas (Hotez, 2017). The World Health Organization (WHO) have implemented 63	
various strategies to combat these diseases, including treatments, surveillance, 64	
improvement of housing, and vector control. These have reduced significantly the 65	
prevalence allowing prediction and may result in the elimination of some diseases, such 66	
as human African trypanosomiasis, in the next years (WHO, 2016). 67	
Chemotherapy against protozoan parasites is a field that needs to improve and different 68	
current challenges are being considered. Several drugs have been used for decades, 69	
but they have limited efficiency, because of the development of drug resistance,  toxicity 70	
issues for patients, and because their administration needs supervision  thus incurring 71	
high costs for the  health system (Klokousas et al, 2003; Hart et al, 2017; Menegon et al, 72	
2016). Hopefully, new antiprotozoan drugs  will be made available in the next few years 73	
to follow the success of Artemisinin for malaria.  74	
Efforts have been made in the post-genomic era to  elucidate metabolic pathways in 75	
parasites with the aim of  discovering specific targets that  may be important for  putative 76	
chemotherapies and also to improve  current drugs used as treatments (Lechartier et al, 77	
2014; reviewed by Weigelt, 2010).  78	
The challenge for improving therapies is a better understanding  of host-parasite 79	
interactions with an improved view on parasite adaptation and how the pathogen is able 80	
to manipulate its host environment. In recent decades, the research in this area has 81	
largely focused on the biomolecules secreted by parasites, many of which down-82	
modulate  host immune responses (reviewed in Evans-Osses et al, 2015). Despite the 83	
progress in this field and the description of secreted products in different parasitic 84	
infections (Kaur et al, 2001; Coakley et al, 2017; Grébaut et al, 2009), little is known 85	
about the mechanism(s) that regulate their interaction during  host-parasite  interaction,.  86	
The current decade has seen immense activity in extracellular vesicle research, with 87	
some suggesting that EV release is the main process  for modifying the phenotype of 88	
neighboring cells. (Szempruch et al, 2016; Kim et al, 2016; Buck et al, 2014). 89	
Physiological release of EVs represents a normal state of the cell raising a metabolic 90	
equilibrium or steady state between catabolic and anabolic processes.   When the cells 91	
are submitted to stress with different inducers or in pathological situations (malignances, 92	
chronic diseases, infectious diseases, etc), they response with an intense and dynamic 93	
release of EVs (Cocucci & Meldolesi, 2015).  94	
Although there is a plethora of literature describing the cargo or content of EVs, there 95	
are very few reports giving an exact description of the mechanism of their release or 96	
providing  a clear understanding  of the role of  EVs in cell-cell communication. 97	
The concept that EVs represent intercellular communicative vectors is based on the idea 98	
that the cells release a compartmentalized cargo with proteins, lipids, nucleic acids, and 99	
biomolecules for uptake and integration into other cells.  The intense flux between cells 100	
of EVs has been described intensively in recent years in many biological systems and 101	
we have summarized the findings in host-parasite interactions in table 1. With the 102	
increasing research in this field, more information has been obtained in characterization 103	
of EVs by the proteomic analysis of EVs  and description of microRNAs contained in 104	
exosomes or microvesicles (MVs) from a variety of cell types (Zhang et al, 2015; Eirin et 105	
al, 2014; Alegre et al, 2014). An integrated platform with the data obtained from 106	
proteomics results is available in Vesiclepedia (Kalra et al, 2012).    107	
During host-pathogen interaction, protozoan cells employ a vast set of evasion 108	
mechanisms to resist the attack of the immune system to penetrate into the organism 109	
and establish the infection. In recent years EVs have been raised as a new element of 110	
pathogens’ evasion mechanisms and modulate parasite-host cell interaction (reviewed 111	
by Evans-Osses et al, 2015; Coakley et al, 2017). In this review, we summarize the role 112	
of EVs  in host-parasite interaction in parasite diseases caused by protozoan parasites. 113	
However, our focus is to discuss the application of the knowledge learned in EVs in 114	
different models to develop alternatives to diagnostic, vaccine and translational 115	
medicine. 116	
EXTRACELLULAR VESICLES HAVE DIFFERENT MODES OF BIOGENESIS 117	
Exosomes and Microvesicles (also called  microparticles, ectosomes) are released from 118	
cells by energy dependent processes  display differences in biogenesis, size, function 119	
and cargo. Exosomes (30–100 nm in diameter) are vesicles formed  upon inward 120	
budding of endosomes resulting in   intraluminal vesicles, within  multivesicular bodies;  121	
exosomes are then released by exocytosis within the secretory pathway (reviewed by 122	
Evans-Osses et al, 2015). Exosomes contain proteins derived from their cell of origin 123	
enriched for MHC class I and II, as well as heat-shock proteins and other proteins.  MVs 124	
however are not derived from endocytosis, forming instead from a budding of the plasma 125	
membrane, occurring in response to activation of  cellular processes (Silva et al, 2017), 126	
in a Ca2+ -dependent manner , and their size varies (100 nm–1 μm). Briefly, external 127	
stimuli, such as interaction with pathogen membranes, or some kind of cell damage 128	
result in  Ca2+influx to the cytoplasm or its release from internal sources. The rise in 129	
intracellular Ca2+  activates the calpain-mediated cleavage of the actin cytoskeleton. 130	
Flippase and floppase are then inhibited and scramblase is activated transporting the 131	
negatively charged phospholipids from the inner to the outer leaflet of the plasma 132	
membrane ( Fujii et al, 2015), resulting in MV formation with phosphatidylserine 133	
exposure. MV content is a reflection of the cellular state (Stratton et al, 2015) and of the 134	
topographic region of the plasma  membrane where it was formed (Figure 1). Isolation	of	135	
EVs	involved	in	host-pathogen	interaction	can	be	performed		from	several	sources,	such	as	cell-136	
protozoan	 in	 vivo	 or	 in	 vitro	 interaction/infection	 and	 also	 from	 parasite	 axenic	 culture.	 In	137	
addition	to	the	in	vitro	approaches,	vesicles	can	be	obtained	from	patients’	and	from	laboratory	138	
animals’	biofluids.	Researchers	use	several	techniques	for	the	isolation	of	EVs,	the	most	common	139	
and	best	accepted	being	differential	centrifugation	and	size	exclusion	chromatography	(Ramirez	140	
et	al.,	2017).	Detection	of	EVs	is	based	on	their	biophysical	properties	and	marker	identification.	141	
The	most	common	detection	procedures	are	Western	blotting,	nanoscale	tracking	analysis	and	142	
electron	microscopy	(Gardiner	et	al,	2016). In addition, protein quantification assays can  be 143	
used to estimate the protein concentration of EVs. 144	
During the long evolution of protozoan species, many pathogens have evolved to invade 145	
a wide range of hosts. Some of these needed to infect host cells to complete the life 146	
cycle and produce an infection. Pathogens need to interact with the immune system 147	
using an array of mechanisms to avoid host immune recognition and effector systems. 148	
The production of EVs is one of these strategies. Protozoan EVs could be involved in 149	
invasiveness, innate recognition, such as the complement system, immunomodulation 150	
and other processes, and this vesicle flux is essential to understand its pathogenicity. 151	
While there is much to be learned about host-parasite interactions, exosomes and  MVs 152	
are involved in the persistence of parasite populations within the host. 153	
INTRACELLULAR PARASITES 154	
Leishmania sp. 155	
Leishmania parasites,the causative agents of leishmaniasis, are spread by the bit of 156	
phebotomine sand flies and the disease  manifests itself differently in people. The first 157	
suggestion of the release of exosome-like vesicles by Leishmania was a description of 158	
a large number  of known eukaryotic exosomal proteins in Leishmania conditioned 159	
medium, suggesting a vesicle-based secretion system (Silverman et al. 2008). Later, 160	
other authors confirmed these findings (Silverman et al. 2010) showing that the release 161	
of leishmanial exosomes is upregulated by infection-like stressors (37°C; ± pH 5.5), also 162	
altering the quantity of vesicles and their protein composition. In the same work, the 163	
uptake of  GFP+ exosomes by infected and non-infected macrophages was observed, 164	
and Leishmania exosomal proteins HSP70 and HSP90 detected in  the cytosol of 165	
infected macrophages with specific antibodies.  The selective induction of IL-8  secretion 166	
in a dose-dependent manner in macrophages treated with exosomes points to an 167	
exosomal delivery of molecular messages to infected as well as neighboring uninfected 168	
macrophages. It has also been shown that , the protein content of purified exosomes 169	
released by macrophages infected with Leishmania mexicana promastigotes displays a 170	
unique composition and abundance of functional groups of proteins, such as plasma 171	
membrane-associated proteins, chaperones and metabolic enzymes  compared to the 172	
exosomal content of macrophages exposed to LPS and exosomal-free medium (Hassani 173	
& Olivier 2013). Macrophages exposed to Leishmania release exosomes containing 174	
parasite surface protease GP63 that can modulate macrophage protein tyrosine 175	
phosphatases and transcription factors in a GP63-dependent manner, playing a notable 176	
role in dampening the innate inflammatory response (Hassani et al. 2014). With a 177	
different focus, total Leishmania RNA was compared with exosomal RNA (Lambertz et 178	
al. 2015) and it was shown that exosomes are selective and specifically enriched in small 179	
RNAs derived almost exclusively from non-coding RNAs, which could have regulatory 180	
functions in cells, influencing host-parasite interactions. The expression and function of 181	
an L. major phosphatase, LmPRL-1, that participates in the intracellular survival of the 182	
parasites inside macrophages was characterized recently (Leitherer et al. 2017) and it 183	
has been shown that this protein is secreted mostly inside exosomes . 184	
 185	
Trypanosoma cruzi  186	
Recognized by WHO as one of the world’s 13 most neglected tropical diseases, Chagas 187	
Disease is caused by the protozoan Trypanosoma cruzi and represents a relevant social 188	
and economic problem mainly in Latin American countries. T. cruzi is able to invade most  189	
eukaryotic cells and has a complex life cycle involving mammalian hosts and insect 190	
vectors (WHO, 2002). The release of EVs has been described in epimastigote, 191	
metacyclic and tissue-derived trypomastigote stages of T. cruzi. These EVs may be 192	
releasedspontaneously or upon  activation and  they are able to interact with host cells 193	
(Gonçalves, M. F. 1991; Neves, 2014; Silveira, 1979; Cestari, 2012; Bayer-Santos, 194	
2013).  Ramirez et al (2017) showed that vesicles obtained by the interaction of parasites 195	
with THP-1 monocytes cells contain components of mutual origin . Analysis of purified 196	
vesicles isolated from the supernatant of infected VERO (African Green Monkey kidney 197	
fibroblast-like) cells indicated that only ~10% of the total proteins detected were of T. 198	
cruzi origin. Also, it was described that cells infected  with metacyclic trypomastigotes 199	
shed vesicles containing GP82, transialidases, gp63, and other parasite proteins 200	
(Bautista-lópez et al. 2017; Bayer-santos et al. 2013). It has been suggested a relevant 201	
role of EVs in interfering with host cell dynamics even before parasite-cell contact is 202	
established. Besides the fact that vesicles isolated from trypomastigote cultures induce 203	
different levels of proinflammatory cytokines and nitric oxide by macrophages in a 204	
heterogeneous manner (Nogueira et al, 2015), the effect of host modulation was shown 205	
in several studies. Microvesicles can also act as an immune evasion mechanism and 206	
result in increased parasite survival. For example, vesicles were shown to form a 207	
complex with C3 convertase, the central enzyme of the complement system, leading to 208	
the decay of the enzyme on the parasite surface. To escape the immune system, T. cruzi 209	
could use microvesicles containing TGF-β, promoting an increase in the number of 210	
intracellular parasites per cell (Cestari et al, 2012; Ramirez et al, 2017). Interestingly, the 211	
phenomenon of increased infectivity and inhibition of the complement system appears 212	
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to be class specific, since vesicles derived from parasites of one class did not alter 213	
complement resistance and the invasion process of parasites from the other class (Wyllie 214	
& Ramirez, 2017). In vivo, it has been shown that  mice previously  inoculated with  EVs 215	
derived from pathogen- host cell interaction from some metacyclic  forms, upon receiving 216	
a challenge with metacyclic trypomastigotes forms from the same strain of T cruzi,   the 217	
parasitemia increases in mice  (Cestari et al, 2012; Ramirez et al, 2017). However when  218	
mice were given an  injection of a vesicle fraction  prior to T. cruzi infection with tissue 219	
culture-derived trypomastigotes, this led to increased death and development of a more 220	
severe pathology compared to controls (Trocoli Torrecilhas et al, 2009). This  221	
consolidates the concept that vesicles induced by parasites contribute to a pro-parasitic 222	
environment. 223	
 224	
  225	
Plasmodium sp. 226	
Malaria is a disease transmitted by Anopheles mosquitoes caused by protozoan 227	
parasites of the genus Plasmodium that infect erythrocyte and hepatocyte cells and was 228	
responsible for 212 million new infections and 429 000 deaths worldwide only in 2015. 229	
Although malaria can be a deadly disease, illness and death from malaria can usually be 230	
prevented (CDC, 2015). Plasmodium falciparum parasites directly communicate with 231	
other parasites and host cells using exosome-like vesicles that carry parasite proteins 232	
and antigens (Martin-Jaular et al, 2011). These are able to deliver  genes, as verified by 233	
their capacity to  transfer drug resistance to parasites (Regev-Rudzk et al, 2013). 234	
Extracellular vesicles promote differentiation of gametocytes, the sexual parasite stage 235	
for disease transmission to mosquito vector (Regev-Rudzk et al, 2013; Mantel et al, 236	
2013).  237	
Extracellular vesicles in Plasmodium infection can activate host immune cells and induce 238	
macrophage to produce proinflammatory cytokines IL-6, IL-12, and IL-1 βand the anti-239	
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inflammatory cytokine IL-10 in a dose-dependent manner (Mantel et al, 2013). Red blood 240	
cells parasitized with Plasmodium produce 10 times greater numbers of  EVs than 241	
unparasitized cells (Nantakomol et al, 2011) and infected patients have higher 242	
frequencies of plasma circulating vesicles compared to healthy controls (Campos et al, 243	
2010). The pathogenic role of EVs was studied in vivo in mice during Plasmodium 244	
infection, where the peak of plasma EVs   coincided with the appearance of neurological 245	
manifestations of cerebral malaria (CM). In this model, fluorescently labelled EVs from 246	
mice with CM were transferred into infected mice and were shown to be attached to the 247	
endothelium of brain vessels. EVs transferred from activated endothelial cells into 248	
healthy recipient mice could induce CM-like histopathological anomalies in brain (El-249	
Assaad et al, 2014). The relation between EV levels and pathology was demonstrated in 250	
patients by Nantakomol et al (2011), whose group  showed that plasma red blood cell–251	
derived ‘microparticle’ concentrations were increased in patients with falciparum malaria 252	
in proportion to disease severity. Another study found increased numbers of circulating 253	
endothelial-derived vesicles in children with coma and severe malaria. In this work it was 254	
also noticeable that during convalescence of the infection the number of endothelial-255	
derived vesicles was significantly less than in the acute stage among patients with 256	
cerebral malaria or coma and severe anemia (Combes et al, 2004).  257	
 258	
Toxoplasma gondii 259	
Toxoplasmosis is caused by Toxoplasma gondii, an intracellular protozoan that 260	
infectsmost nucleated cells found worldwide. T. gondii infection may be asymptomatic in 261	
immunocompetent individuals, but may cause severe, life-threatening illness in 262	
immunocompromised individuals and fetal complications if the mother experiences 263	
primary infection during pregnancy (Beauvillain et al. 2009). Knowledge about exosomes 264	
secreted by T. gondii, or by cells infected by the protozoan is still very limited (Dlugonska 265	
& Gatkowska, 2016; Wowk et al, 2017).  Pope & Lässer (2013)  hypothesize that 266	
exosome-like particles derived from T. gondii-infected fibroblasts could participate in the 267	
pathogenesis of the parasite, and could be responsible for increasing mRNA levels 268	
associated with neurological activity (Rab-13, thymosin) and their transfer to uninfected 269	
cells. The first proteomic profile from EVs of T. gondii, obtained from infected human 270	
foreskin fibroblast, reveals biomolecules already described in other models, such as 271	
CD63, HSP 70, and calcium-binding proteins (Wowk et al, 2017). Kim et al. (2016) 272	
observed changes in the proliferation of myoblasts treated with exosomes derived from 273	
infected cells (increase in the S phase).  274	
 275	
EXTRACELLULAR PARASITES 276	
Giardia intestinalis  277	
G. intestinalis is one of the most prevalent gastrointestinal pathogens on the planet that 278	
produce a diarrhoea with low inflammation and in some cases a chronic infection. The 279	
replicative form trophozoites need to adhere to the small intestine mucosa for survival. 280	
Secretory products involved in the communication between leukocytes by parasites was 281	
reported by Lee et al (2012): Trophozoites of G. intestinalis   stimulated the production 282	
of IL-8  which wase responsible for the recruitment of neutrophils. As reviewed by Evans-283	
Osses et al (2015), it is suggested that the EVs represent an important form of 284	
communication and immunomodulation. Evans-Osses et al. (2017) identified the release 285	
of MVs from G. intestinalis, for the first time. The release of MVs may vary at different 286	
pH conditions (7.0 being the best condition) and time, and their release increases the 287	
adhesion capacity of the protozoa in Caco-2 (Caucasian colon adenocarcinoma cells) 288	
and their uptake and maturation by human dendritic cells. The pathogenesis of Giardia 289	
is not yet fully understood. Kho et al (2013) demonstrated that HCT-8 (ileocecal 290	
colorectal adenocarcinoma cells) infection could induce apoptosis, with signs of 291	
chromatin condensation and activation of caspase-3. It was demonstrated that extracts 292	
of parasites in contact with Caco-2 induced apoptosis, showing that the presence of the 293	
parasite is not necessary to start the process and suggesting that it could be dependent 294	
on EVs.  295	
 296	
Trypanosoma brucei 297	
Nten et al (2010) identified for the first time that secretomes of T. brucei  (T. brucei brucei, 298	
T. brucei gambiense) are associated with the pathway of exosomal biogenesis, being 299	
composed of proteins associated with pathological processes and the evasion of the 300	
immune system (metalopeptidases, Gp63 protease). Eliaz et al. (2017) demonstrated 301	
that exosome secretion was inhibited in T. brucei when transcription is inhibited (Vps 36), 302	
but production of exosomes continued in nanotubes. In addition, EVs could interfere in 303	
the social motility of parasites, repelling individuals from unfavorable conditions. Using 304	
time-lapse microscopy, it was demonstrated that exosomes were secreted for the 305	
transmission of stress signals. Szempruch et al (2016) concluded that exosomes contain 306	
mostly flagellar and membrane proteins, such as surface glycoproteins and HSP-70. 307	
These particles merge with erythrocytes, causing a decrease in circulation, and possibly 308	
resulting in host anemia.  Furthermore, T. brucei rhodesiense can transfer vesicles 309	
containing serum resistance-associated proteins to non-human trypanosomes, allowing 310	
immune system evasion. A number of proteins contained in exosomes of T. brucei 311	
gambiense (HSP-70, RAB protein, α and β tubulins, heavy chains of  clathrin, histamine) 312	
have been identified (Geiger et al. 2010), with physiological functions not only for survival 313	
in the host, but also for immunomodulation and intercellular communication. Enzymes 314	
involved in nucleotide metabolism were also identified, which could influence the 315	
inflammatory process.  316	
 317	
Trichomonas vaginalis 318	
Trichomonas vaginalis colonizes the human urogenital tract producing sexually 319	
transmitted disease known as trichomoniasis. Twu et al. (2013) identified for the first time 320	
the participation of T. vaginalis exosomes in immunomodulation and host-parasite 321	
communication, allowing an improvement of adhesion when exosomes from highly 322	
adhesive parasites were incubated with a less adhesive parasite. Olmos-Ortiz et al 323	
(2017) observed the immunomodulatory effects of T. vaginalis exosomes on murine 324	
macrophages. These vesicles induced an increase of IL-10, Il-6, TNF-α expression, and 325	
nitric oxide production (cytotoxic and immunomodulatory activity). In addition, infected 326	
mice treated with exosomes increased IL-10 production and decreased IL-17 levels, 327	
resulting in the diminution of the inflammatory process without a reduction in parasitic 328	
load.  329	
 330	
WHAT IS THE NEXT STEP: TRANSLATIONAL APPLICATIONS. 331	
The apparent role of EVs in a large number of biological processes, along with many of 332	
their intriguing features, forms the basis of extending EV analysis beyond basic research 333	
and into the clinical and therapeutic context (Revenfeld et al, 2014). EV isolation methods 334	
should be more specific, to ensure  safe therapeutic possibilities (Momem-Heravi et al, 335	
2014; Alvarez-Erviti et al, 2011; Zhou et al, 2013). In this regard, the development of 336	
portable point-of-care diagnostic tools for detecting circulating exosomes as biomarkers, 337	
should be important in the future. Although much effort has been employed   to 338	
understand  the biology of EVs, we still need more experimental advancements to 339	
develop applied methods for the community. The need  for such diagnostic tools in 340	
developing countries are very important as many  are burdened by parasitic diseases, 341	
and lack professional and material resources.  342	
While naturally secreted exosomes may mediate beneficial effects in certain disease 343	
conditions, targeted exosomes loaded with therapeutic molecules may optimize efficacy 344	
while also reducing off-target delivery (Barile & Vassali, 2017; Moore et al., 2017) The 345	
lipid composition of their membranes may also increase antigenic stimulation (Zitvogel 346	
et al, 1998; Escudier et al, 2005). It is now imperative  that the findings  from basic 347	
research are translated into biotechnological applications with greater urgency (Fontana 348	
et al, 2012). 349	
 350	
 351	
Vaccines 352	
Among numerous biomedical applications, the use of EVs in immunization may be 353	
explored in the future. The way EVs interact in antigen presentation allows the possibility 354	
of its use in developing a T cell-dependent response. In the past decade, it is laudable 355	
that philanthropic initiatives have been involved in the production of vaccines, since 356	
diseases caused by unicellular eukaryotes are a major burden to tropical developing 357	
countries.   358	
The genome of many protozoa has already been studied, and others have been initiated 359	
for the study of transcriptomes (Birkeland et al, 2010; Rastrojo et al, 2013; Morse et al, 360	
2016). However, for ethical reasons, it is not possible to use live cell lines in an 361	
immunization protocol in humans (Beauvillain et al, 2009), especially considering the 362	
contraindication of live attenuated  vaccines for  immunocompromised patients. 363	
Exosomes could therefore provide a new method for communication and for the 364	
exchange of antigenic information between cells in the immune system (Aline et al, 365	
2004). Since they are of the same size as viruses, a similar uptake by antigen-presenting 366	
cells may be observed. Interestingly, the use of exosomes as a versatile tool for signal 367	
delivery compared with soluble molecules is gaining support due to their double-layered 368	
membrane (Trelis et al, 2016). In eukaryotic pathogens, both immuno-stimulatory and 369	
immuno-inhibitory functions have been reported for exosomes (Atayde et al, 2016).  The 370	
ability of exosomes, especially those derived from dendritic cells (DCs), to induce 371	
protective immune responses offers an alternative to DC-based vaccines (Beauvillain et 372	
al, 2007). Dendritic cells, presenters of antigens that participate in the onset of the 373	
adaptive response, are able to secrete EVs  carrying  MHC class II antigens, allowing 374	
the development of a specific  T cell response; these EVs would be antigen-presenting 375	
vesicles (Zitvogel et al, 1998; Escudier et al, 2005).. Intracellular parasites, bacteria, and 376	
viruses that enter cells via an endocytotic pathway are prime candidates for DC-based 377	
exosome Immunogens. Vaccines consisting of exosomes will both preserve the positive 378	
aspects of live parasite vaccines and avoid their inherent risks (del Cacho et al, 2012). 379	
Aline et al (2004) demonstrated for the first time the participation of exosomes in 380	
protection against pathogens. They developed a vaccine composed of exosomes of DCs  381	
stimulated by T. gondii, capable of eliciting a TH1-mediated response. This protective 382	
capacity may be associated with DCs or exosome trafficking. Dendritic cells stimulated 383	
in vitro with T. gondii antigens secreted exosomes capable of inducing a significant 384	
humoral responses in syngeneic and allogeneic mice, with a greater participation of IgA 385	
and reduction of cysts in the brain. Due to the low safety of administering an attenuated 386	
T. gondii vaccine to humans (Beauvillain et al, 2007), the use of antigen-presenting 387	
vesicles is a possible way of stimulating T cells. 388	
Exogenous derivatives of DCs, stimulated with Leishmania major antigens, created a 389	
protective response with TH1 activation against cutaneous leishmaniasis (Schnitzer et 390	
al, 2010). 391	
Martin-Jaular et al (2011) verified increased IgG in mice by treating them with exosomes 392	
of reticulocytes infected with Plasmodium yoelli. Antibodies were able to recognize 393	
erythrocytes infected with the protozoan. A summary of EVs involved in immunity is 394	
shown in Table 2. A summary of EVs involved in immunity is shown in Table 2 and some 395	
of possible strategies are illustrated schematically  in Figure 2 and 3. 396	
 397	
However, although the use of exosomes allows for a cell-based vaccine, there are both 398	
conceptual and practical issues that need to be addressed before this potential 399	
application can become a reality. These include obtaining exosomes with the correct mix 400	
of antigens that provide protection, with the risks of introducing 'non-self' human 401	
molecules into a vaccinated individual (Schorey et al, 2015).Through EVs, protozoa are 402	
able to initiate proinflammatory responses from target cells, such as increased 403	
production of interleukins. Therefore, it is suggested that the vesicles may have the 404	
added benefit of acting as adjuvants. Exosomes have also been shown to induce anti-405	
tumor immunity in the absence of adjuvants or heat treatment (Greening et al, 2015; 406	
Morishita et al, 2016) thus suggesting the use of exosomes as adjuvant carriers because 407	
of the ability of these structures to act as molecule carriers. Due to their physical 408	
properties, EVs could enhance the immunogenicity of antigens.  A satisfactory response 409	
must activate specific arms of the immune system, such as the cell-mediated response, 410	
and possibly constitute an effective immunomodulatory effect for diseases that lack an 411	
effective immunogen.  412	
 413	
Diagnostic  414	
The level of EVs in human serum could be a marker of disease status (Pisitkun et al, 415	
2004; Wekesa et al, 2014; Kim et al, 2017).  As EVs reflect the proteomic content of the 416	
cells from which they are derived, it is possible to use them for disease detection, as first 417	
investigated in tumors (Santiago-Dieppa et al, 2014). EV cargo can also be involved in 418	
disease prognosis. The nature of the vesicles allows a means of transport, free of blood 419	
degradation. This has proven to be particularly significant for the use of miRNA as 420	
valuable biomarkers because most RNA in blood exists within EVs (Revenfeld et al, 421	
2014).  Recently,  Melo et al (2015) detected cancer-cell derived exosomes containing a 422	
high concentration of cell surface proteoglycan, glypican-1. It was showed that glypican-423	
1 is a pan-specific marker of cancer exosomes, specifically detected in the serum of 424	
individuals with pancreatic cancer. Many parasitic diseases have parasite-host 425	
interactions with poorly studied pathogenesis. As EVs participate in these processes, 426	
clinical investigation should consider the detection of EVs derived from parasites or hosts 427	
in biological fluids. When the T. cruzi secretome was analyzed after 16 hours of 428	
ultracentrifugation,  proteins involved in the pathogenicity of the protozoa, such as GP63 429	
and Aminopeptidase P, were found to be increased within the EVs compared to  the 430	
supernatant fraction (Bayer-Santos et al, 2014). According to Geiger et al. (2010) 431	
metallopeptidase thimet oligopeptidase A (M3 family) is the first of the group to be 432	
identified in Protozoa, resulting in a potential marker for diagnosis in T. brucei. The 433	
presence of proteins on the EV lipid bilayer such as the tetraspanins, could present  434	
targets for detection by monoclonal antibodies .  435	
It is also possible that nucleic acid ,present in EVs has  some diagnostic potential (Melo 436	
et al, 2015;, Zhang et al, 2015; Eirin et al, 2014). Such a molecular diagnosis of parasitic 437	
diseases offers high sensitivity and specificity, compared to microscopic examination,  438	
reducing shortcomings and it can be standardized (Stensvold et al, 2011). As microscopy 439	
remains labour intensive and highly observer-dependent, molecular detection 440	
techniques, such as real-time PCR, are excellent alternatives, in particular in settings 441	
where the number and range of parasitic infections is low and personnel costs are 442	
substantial (Lieshout & Roestenberg, 2015). Serological assays also have limitations. 443	
For example, conventional serological assays for T. cruzi may lead to unspecific 444	
reactions (false positives) due to cross reactivity with antibodies elicited by other 445	
pathogens, e.g., Leishmania spp. and Trypanosoma rangeli. Because of a lack of a 446	
single test with high sensitivity/specificity, the WHO recommends positive results from 447	
two different serological tests for a confirmation of T. cruzi infection (Zingales, 2017). In 448	
that context, diagnostic techniques based on molecular targets are becoming more 449	
popular.  450	
Accordingly, as reviewed by Inamdar et al (2017), expression profiling can be useful as 451	
a diagnostic tool in diseases that lack definitive biomolecular biomarkers. The detection 452	
of nucleic acids  in EVs obtained from clinical samples, like feces, could become a regular 453	
procedure . It was shown by Liu et al, (2016)  that is possible to obtain a suitable  Fecal 454	
Suspension Particle size Distribution by NanoSight and EM Feces from  mice with a 455	
combination of  dilution of feces  in PBS , spun down at 10,000 ×g for 5 min  by 456	
centrifugation and  then filtered  to remove the debris. Moreover, EVs were isolated from 457	
feces homogenized in PBS, using exoEasy Maxi Spin Columns (Qiagen), followed by  458	
RNA isolation using miRCURY RNA isolation kit (Exiqon) with on-column DNase 459	
treatment (Qiagen). 460	
 Other types of analytes that could be studied in the exosomal space, such as lipids, 461	
might represent good biomarkers to investigate in the near future. All these provide an 462	
important base to continue research in parasite-derived exosomes as diagnostic targets 463	
and demonstrating their utility as clinical biomarkers (Sánchez-Ovejero et al, 2016).  464	
Therapeutics 465	
Extracellular vesicles participate in cellular traffic thereby influencing pathophysiological 466	
conditions and it is this  capacity to be delivered that could be extrapolated for therapeutic 467	
purposes as well (Moore et al., 2017). Mammalian stem cells EVs have been   shown to 468	
be involved in cell proliferation and improved renal function of cisplatin-induced  acute 469	
kidney injury in rats (Zhou et al, 2013). For the same model, it was also demonstrated 470	
that exosomes could deliver miRNA for up-regulation of anti-apoptosis genes, and 471	
reduce mortality caused by cisplatin (Bruno et al, 2012).  Intranasal delivered exosomes 472	
were taken up by microglial cells, which are key mediators in neuro-inflammatory 473	
diseases; delivery of curcumin-loaded exosomes resulted in a reduction in activated 474	
microglial cells in both encephalitis and LPS-induced brain inflammation models (as 475	
reviewed by Inamdar et al, 2017).   476	
There are different ways to explore the potential of therapeutic EVs. For example, 477	
macrophage-derived MVs may represent a way of converting an autologous intrinsically 478	
biocompatible sub-cellular entity into a drug delivery system able to carry both 479	
nanoparticles and drugs. In this regard, it would be of interest to demonstrate that cellular 480	
Comment	[JI4]:	?? 
MVs might be loaded with different drug molecules while simultaneously enclosing 481	
nanoparticles that enable spatially controlled drug delivery.  482	
 Silva et al (2015) encapsulated different drugs with magnetic nanoparticles within MVs. 483	
The magnetic properties of the nanoparticles could influence  the uptake of the loaded 484	
MVs, and such a combination could represent a model for the delivery of different types 485	
of drugs, as for example in cancer-therapy. The possibility of producing MVs from 486	
different cell populations could improve such association, resulting in a specific delivery 487	
method. Strategies for loading molecular cargo in exosomes and related efficacies differ 488	
based on the chemistry of the loaded molecule (as reviewed by Inamdar et al, 2017).  In 489	
this regard, it is possible to explore the loading capacity of EVs for different antiprotozoal 490	
drugs. 491	
Besides drug delivery, nucleic acids have also been involved in therapeutic purposes. 492	
The specificity imparted by targeted exosomes, the ability to load exogenous genetic 493	
cargoes, the ability to systemically administer the gene therapy and immune evasion by 494	
exosomes are valuable properties for future oligonucleotide therapy applications 495	
(Alvarez-Erviti et al, 2011). In addition, exosome-transferred miRNAs are emerging as 496	
novel regulators of cellular function (Alexander et al, 2015). Momem-Heravi et al (2014) 497	
loaded exosomes with microRNA (miR-155, with electroporation) or inhibitor to be 498	
uptaken by hepatocytes or macrophages, respectively. Exosome-mediated inhibition 499	
was superior to conventional transfection models. Alvarez-Erviti et al (2011) through in 500	
vivo administration of exosome-loaded siRNA were able to specifically knockdown BACE 501	
1 (protease involved in Alzheimer´s Disease).  502	
Delivery of drugs or nucleic acids though EVs to treat parasitic diseases have not been 503	
explored yet. However, mammalian models shows promise. We speculate that if EV-504	
loaded microRNAs inhibit genes involved in the pathogenesis of protozoa, it will 505	
significantly affect parasite-host interactions. MicroRNA could specifically regulate 506	
protozoan virulence through inhibition of invasiveness-related genes, or improve the host 507	
Comment	[IR5]:	Especulate 
immune system by up-regulating immune-related genes. Another promising strategy 508	
relies on gene-editing tools, like CRISPR/Cas 9.  CRISPR/Cas 9 is a technology based on a 509	
known mechanism from bacteria and archaea that enable the organisms to respond to and 510	
eliminate invading genetic material. The CRISPR/Cas9 system consists of the Cas9 511	
nuclease and a single guide RNA, which are used to guide effector endonucleases that target 512	
interested DNA sequence based on sequence complementarity (Chira et al, 2017). While in 513	
vivo delivery of this system has a low efficiency, the use of exosomes loaded with 514	
CRISPR/Cas9 showed a promising result in cancer. Kim et al (2017) demonstrated a 515	
reduced apoptosis in ovarian cancer by suppressing poly (ADP-ribose) polymerase-1, 516	
with CRISPR/CAs9 loaded exosomes.	While there is a long way in medical approaches 517	
concerning the application of this tool, a CRISPR/Cas9 system editing pathogen genes 518	
will allow a better  understanding  about host-pathogen interaction. This knowledge could 519	
provide  the possibility of  designing novel targets for  therapeutic interventions .   520	
 521	
  522	
 523	
CURRENTL REMARKS  524	
The strategies debated in this work are speculations of what is to come from the rapidly 525	
expanding field of EVs. It is clear that “trial-and-error” research is necessary to expand 526	
applications in the routine  medical laboratory. Since parasitic diseases are common in 527	
developing countries, translation into clinics must involve low-cost strategies. If 528	
participation of EVs in cell communication models are becoming highly proven, it is only 529	
a matter of time until  biotechnology is able to deliver  accessible procedures. 530	
Ar EV-detection methods going to emerge as markers for next-generation diagnostics of 531	
protozoa?  532	
Are EVs a satisfactory alternative for the immunization of poorly responsive populations? 533	
Can EVs be considered a delivery system for drugs to reduce off-target effects on 534	
parasitological diseases? 535	
Is Clinical parasitology going to translate extracellular vesicle-based research in the 536	
future?  537	
Can gene-editing systems interfere in host-parasite communication, acting as a 538	
therapeutic alternative? 539	
 540	
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